Literature DB >> 8790223

Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells.

J R Ballinger1, J Bannerman, I Boxen, P Firby, N G Hartman, M J Moore.   

Abstract

UNLABELLED: The accumulation of 99mTc-tetrofosmin (TFos) was studied in wildtype (WT) and doxorubicin-resistant (AdrR) variants of the rat MatB and human MCF-7 breast tumor cell lines to determine whether TFos, like 99mTc-sestamibi (MIBI), is a substrate for P-glycoprotein (P-gp), a multidrug-resistance transporter.
METHODS: The time course of accumulation of TFos and MIBI in WT and AdrR cells over 1 hr was studied using single-cell suspensions at 1 x 10(6) cells/ml incubated at 37 degrees C in the presence or absence of PSC833, a potent modulator of P-gp. Modulator dose-response curves were generated for PSC833, cyclosporin A, and verapamil.
RESULTS: In both MatB and MCF-7 cells, TFos and MIBI accumulated extensively in WT cells and accumulation was not affected by PSC833. In contrast, ADrR cell lines accumulated very little of either tracer, but addition of PSC833 or other modulator increased this accumulation in a dose-dependent fashion. TFos and MIBI did not differ significantly in their behavior.
CONCLUSION: TFos shares with MIBI the property of being a substrate for P-gp and thus TFos may be useful for functional imaging of tumor P-gp status.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8790223

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody.

Authors:  Julliëtte E M van Eerd; Lioe-Fee de Geus-Oei; Wim J G Oyen; Frans H M Corstens; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

2.  Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; Lars R Furenlid; Donald W Wilson; George A Kastis; Michael Bettan; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2005-08       Impact factor: 2.408

3.  Synthesis and Characterization of a Tetramethyl Furanone Functionalized Diiminedioxime, A Potential Ligand for Cu Radiopharmaceuticals, and its Copper(II) and Nickel(II) Complexes.

Authors:  Salma Kiani; Richard J Staples; S Ted Treves; Alan B Packard
Journal:  Polyhedron       Date:  2009-03-12       Impact factor: 3.052

Review 4.  Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients.

Authors:  Giuseppe Madeddu; Angela Spanu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

Review 5.  99mTc-MIBI in the evaluation of breast cancer biology.

Authors:  Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

6.  Imaging recognition of multidrug resistance in human breast tumors using 99mTc-labeled monocationic agents and a high-resolution stationary SPECT system.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; George A Kastis; Michael Bettan; Lars R Furenlid; Donald W Wilson; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2004-01       Impact factor: 2.408

7.  The Promises of Quantitative Proteomics in Precision Medicine.

Authors:  Bhagwat Prasad; Marc Vrana; Aanchal Mehrotra; Katherine Johnson; Deepak Kumar Bhatt
Journal:  J Pharm Sci       Date:  2016-12-08       Impact factor: 3.534

8.  Functional imaging techniques for evaluation of sarcomas.

Authors:  Rodney J Hicks
Journal:  Cancer Imaging       Date:  2005-06-21       Impact factor: 3.909

9.  Dual-phase 99mTc-MIBI imaging and the expressions of P-gp, GST-π, and MRP1 in hyperparathyroidism.

Authors:  Jianjun Xue; Yan Liu; Danrong Yang; Yan Yu; Qianqian Geng; Ting Ji; Lulu Yang; Qi Wang; Yuanbo Wang; Xueni Lu; Aimin Yang
Journal:  Nucl Med Commun       Date:  2017-10       Impact factor: 1.690

10.  Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function.

Authors:  T Muzzammil; M J Moore; D Hedley; J R Ballinger
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.